Development and RNA - Clinical Research Informer

Bayer partners with RNA drugmaker to develop new cancer therapies

Bio Pharma Dive

AUGUST 28, 2024

Under a collaboration with NextRNA Therapeutics, Bayer will access the biotech’s platform to target long, non-coding RNA interactions with small molecule drugs.

RNA

RNA Development Drugs

Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure

Pharmaceutical Technology

SEPTEMBER 9, 2022

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). It is expected to expedite the development of a wide range of new therapeutics using the small non-coding area of the genome that is not explored.

RNA

RNA Development Gene Therapy Gene

Seattle institute lands $18m funding to develop RNA vaccine for chikungunya

Pharmaceutical Technology

AUGUST 3, 2023

AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.

RNA

RNA Vaccination Vaccine Development

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Amgen partners with Arrakis to develop drugs aimed at RNA

Bio Pharma Dive

JANUARY 11, 2022

Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more.

RNA

RNA Drugs Development

Triastek and BioNTech to develop 3D-printed RNA therapeutics

Pharmaceutical Technology

JULY 24, 2024

BioNTech and Triastek have entered a research partnership focusing on the development of 3D-printed oral RNA therapeutics.

RNA

RNA Development Research

Tetra and Cellvera partner to develop oral Covid-19 treatment

Pharmaceutical Technology

SEPTEMBER 8, 2022

Tetra Bio-Pharma and Cellvera have entered an agreement to jointly develop ARDS-003 as an oral combination therapeutic candidate with 400mg Qifenda (Favipiravir) for Covid-19. Developed by FujiFilm Toyama Chemical, Favipiravir is currently owned by Cellvera. Qifenda is a broad-spectrum antiviral drug in the commercial stage.

Development

Development RNA Containment Drugs

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.

Genetics

Genetics Medicine Development Gene Therapy

ReviR Therapeutics partners with Asieris to develop new oncology therapies

Pharmaceutical Technology

FEBRUARY 9, 2023

The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. The company’s VoyageR AI platform integrates computational methods to drug traditionally undruggable RNA targets.

Development

Development RNA Gene Therapy Genetics

BioNTech targets infectious diseases for vaccine development

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. However, following its launch of the world’s first Omicron BA.4/BA.5

Vaccination

Vaccination Vaccine Development Clinical Trials

Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

Bio Pharma Dive

APRIL 22, 2024

billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8

RNA

RNA Development Drugs Research

Cyagen and Neurophth partner to develop gene therapy vectors

Pharmaceutical Technology

NOVEMBER 8, 2022

Cyagen and Neurophth Therapeutics have entered a strategic partnership to jointly develop next-generation AAV gene therapy vectors for specific kinds of genetic ophthalmic ailments. Additionally, Neurophth will oversee the clinical trials and marketing of gene therapy products developed leveraging the new AAV capsids of Cyagen.

Gene Therapy

Gene Therapy Gene Development Genetics

Ascidian and Roche to develop RNA therapies for neurological diseases

Pharmaceutical Technology

JUNE 19, 2024

Ascidian has entered a research partnership and licensing agreement with Roche to develop RNA therapies for neurological diseases.

RNA

RNA Development Licensing Licensing

ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs

Bio Pharma Dive

MAY 23, 2023

Staffed by many former Alnylam and Moderna employees, the startup is developing technologies that could be useful in a variety of RNA drugmaking methods.

RNA

RNA Drugs Development

How did pharma develop a vaccine so quickly?

World of DTC Marketing

DECEMBER 29, 2020

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The post How did pharma develop a vaccine so quickly?

Vaccination

Vaccination Vaccine Development Clinical Trials

Roche joins startup Remix in bet on another way to drug RNA

Bio Pharma Dive

JANUARY 3, 2024

The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.

RNA

RNA Drugs Development

Roche adds to RNA drug deal streak with Ribometrix partnership

Bio Pharma Dive

JANUARY 6, 2021

The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules.

RNA

RNA Drugs Development

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.

Vaccination

Vaccination Vaccine Development Immune Response

Ethris and Heqet team up for RNA-based therapeutic development

Pharmaceutical Technology

NOVEMBER 13, 2023

Heqet Therapeutics and Ethris have collaborated to develop RNA-based therapeutics to treat cardiovascular conditions.

RNA

RNA Development

GreenLight and US NIH partner to develop Covid-19 vaccine for variants

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination

Vaccination Vaccine Development RNA

Flamingo gets grant from VLAIO to accelerate RNA-focused oncology portfolio

Pharmaceutical Technology

JUNE 16, 2023

from Flanders Innovation & Entrepreneurship (VLAIO) to further advance its oncology portfolio targeting RNA. It will also support the firm’s preclinical effort on the long non-coding RNA (LncRNA) programme, FTX-001, that targets MALAT-1. Flamingo Therapeutics has received a research grant of €1.7m

RNA

RNA Gene Therapy Gene Clinical Trials

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

JULY 29, 2022

Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. Their platform identifies which regRNAs control the specific gene of interest.

RNA

RNA Gene Expression Gene Gene Therapy

Chinook and Ionis partner to develop ASO therapy for kidney disease

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. The collaboration aims to discover, develop and commercialise an ASO therapy.

Development

Development Protein RNA Genetics

Daiichi Sankyo and Depixus partner to accelerate RNA-targeted drug discovery

Pharmaceutical Technology

DECEMBER 13, 2023

Daiichi Sankyo plans to leverage the French startup’s technology to develop its RNA-targeted therapeutics pipeline.

RNA

RNA Drugs Development

Two RNA-binding proteins could contribute to cancer therapy development

Pharma Times

APRIL 26, 2024

The paper identifies the roles of LARP4A and LARP4B in sarcoma and carcinoma cancers

RNA

RNA Protein Development

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA

RNA Vaccination Vaccine In-Vivo

Moderna inks another gene editing deal

Bio Pharma Dive

FEBRUARY 22, 2023

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

Gene Editing

Gene Editing Gene In-Vivo RNA

Eli Lilly adds ALS drug prospect with QurAlis deal

Bio Pharma Dive

JUNE 3, 2024

The alliance hands Lilly an RNA-based therapy in preclinical testing for ALS and frontotemporal dementia, and includes a research collaboration to develop other, similar medicines.

RNA

RNA Medicine Drugs Development

Sanofi signs mRNA vaccine development deal with IDT Australia

Pharmaceutical Technology

APRIL 16, 2024

Sanofi has signed an agreement with IDT Australia for preclinical formulation development of its messenger RNA (mRNA) vaccines.

Vaccination

Vaccination Vaccine Development RNA

Benchling launches purpose-built tools to accelerate RNA R&D

BioPharma Reporter

SEPTEMBER 7, 2022

Technology firm, Benchling, has developed what it calls the biopharma industryâs first set of full capabilities for designing, modelling, and studying both natural and chemically modified RNA in a single platform.

RNA

RNA Development

SK pharmteco and Rznomics sign MoU to develop gene therapies

Pharmaceutical Technology

AUGUST 6, 2024

SK pharmteco has entered an MoU with South Korea-based Rznomics for the development and manufacture of RNA-based gene therapies.

Gene Therapy

Gene Therapy Gene Development RNA

Scientists develop an RNA-based breath test to detect COVID-19

Scienmag

DECEMBER 13, 2021

Philadelphia, December 13, 2021 – In a new study in The Journal of Molecular Diagnostics, published by Elsevier, investigators report on the design and testing of a breathalyzer, known as the Bubbler, that relies on viral RNA detection to diagnose SARS-CoV-2.

RNA

RNA Scientist Development Medicine

BioNTech Founders Predict Cancer Vaccine Is Only Years Away

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 16, 2022

The husband-and-wife team who co-founded BioNTech, the biotechnology company that partnered with Pfizer to develop an effective messenger-RNA (mRNA) shot against COVID-19, has predicted that a cancer vaccine could be widely available within the next decade.

Vaccination

Vaccination Vaccine RNA Development

Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies

BioSpace

JUNE 17, 2024

billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases. Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8

RNA

RNA Development

Ipsen and Skyhawk partner to develop rare neurological therapies

Pharmaceutical Technology

APRIL 23, 2024

Ipsen has entered an exclusive global collaboration with Skyhawk Therapeutics for the discovery and development of new small molecules that can modulate RNA for treating rare neurological disorders.

Development

Development RNA

Moderna to develop mRNA therapeutic for very rare disease

BioPharma Reporter

SEPTEMBER 7, 2021

Moderna and the nonprofit Institute for Life Changing Medicines (ILCM) are collaborating to develop a new messenger RNA (mRNA) therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

Development

Development RNA Medicine Regulation

Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised

Pharmaceutical Technology

MAY 15, 2024

CircRNA is still in early days of development, but could be in trials as vaccines, therapeutics and biomarkers in the next few years.

RNA

RNA Vaccination Vaccine Trials

Comanche Biopharma raises $75M to fund preeclampsia drug testing

Bio Pharma Dive

JANUARY 17, 2024

The biotech is developing an RNA-based therapy for what it describes as a root cause of the pregnancy-related complication, which affects millions of women.

RNA

RNA Drugs Development

University of Birmingham researchers develop rapid COVID-19 RNA test

Pharma Times

JANUARY 6, 2021

Test can give accurate results in under five minutes, according to researchers

RNA

RNA Research Development

UTSW study: RNA exosome key for B cell development

Scienmag

JUNE 13, 2022

New research from UT Southwestern suggests that RNA exosomes – the cellular machines that degrade old molecules of RNA – play a key role in the development of B cells, which are critical to the immune system’s ability to protect against infection.

RNA

RNA Development Gene Research

miRecule and Sanofi partner to develop muscular dystrophy therapy

Pharmaceutical Technology

OCTOBER 5, 2022

miRecule and Sanofi have entered a strategic partnership and exclusive licence agreement for the development and commercialisation of an antibody-RNA conjugate (ARC) to treat facioscapulohumeral muscular dystrophy (FSHD). The anti-DUX4 RNA therapy was discovered using the DREAmiR platform of miRecule.

Development

Development RNA Gene Therapy Sales

New open-source software automates RNA analysis to speed up research and drug development

Scienmag

MAY 3, 2022

LA JOLLA, CA—Scientists at Scripps Research have unveiled a new software tool for studying RNA (ribonucleic acid) molecules, which have a host of critical roles in organisms. The app […].

RNA

RNA Development Research Drugs

Laronde sets out to advance Endless RNA: ‘eRNA therapeutics have the potential to be an essential and widespread class of medicines’

BioPharma Reporter

MAY 10, 2021

Flagship Pioneering has unveiled Laronde: a platform company developing Endless RNA.

RNA

RNA Engineer Medicine Protein

Scientists develop RNA-targeting strategy to repair genetic cause of ALS and dementia

Medical Xpress

NOVEMBER 22, 2022

Scientists at University of Florida (UF) Scripps Biomedical Research have developed a potential medicine for a leading cause of ALS and dementia that works by eliminating disease-causing segments of RNA. The compound restored the health of neurons in the lab and rescued mice with the disease.

RNA

RNA Scientist Genetics Development

Ipsen, Skyhawk Ink Potential $1.8B Deal to Target RNA in Neuro Diseases

BioSpace

APRIL 21, 2024

Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.

RNA

RNA Development Drugs Research

Bayer partners with RNA drugmaker to develop new cancer therapies

Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure

Webinars

Trending Sources

Seattle institute lands $18m funding to develop RNA vaccine for chikungunya

Webinars

Amgen partners with Arrakis to develop drugs aimed at RNA

Triastek and BioNTech to develop 3D-printed RNA therapeutics

Tetra and Cellvera partner to develop oral Covid-19 treatment

Lilly and ProQR to expand genetic medicine development agreement

ReviR Therapeutics partners with Asieris to develop new oncology therapies

BioNTech targets infectious diseases for vaccine development

Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

Cyagen and Neurophth partner to develop gene therapy vectors

Ascidian and Roche to develop RNA therapies for neurological diseases

ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs

How did pharma develop a vaccine so quickly?

Roche joins startup Remix in bet on another way to drug RNA

Roche adds to RNA drug deal streak with Ribometrix partnership

Merck and Moderna partner to develop and sell cancer vaccine

Ethris and Heqet team up for RNA-based therapeutic development

GreenLight and US NIH partner to develop Covid-19 vaccine for variants

Flamingo gets grant from VLAIO to accelerate RNA-focused oncology portfolio

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Chinook and Ionis partner to develop ASO therapy for kidney disease

Daiichi Sankyo and Depixus partner to accelerate RNA-targeted drug discovery

Two RNA-binding proteins could contribute to cancer therapy development

Merck and Orna partner for RNA technology-based vaccines and therapies

Moderna inks another gene editing deal

Eli Lilly adds ALS drug prospect with QurAlis deal

Sanofi signs mRNA vaccine development deal with IDT Australia

Benchling launches purpose-built tools to accelerate RNA R&D

SK pharmteco and Rznomics sign MoU to develop gene therapies

Scientists develop an RNA-based breath test to detect COVID-19

BioNTech Founders Predict Cancer Vaccine Is Only Years Away

Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies

Ipsen and Skyhawk partner to develop rare neurological therapies

Moderna to develop mRNA therapeutic for very rare disease

Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised

Comanche Biopharma raises $75M to fund preeclampsia drug testing

University of Birmingham researchers develop rapid COVID-19 RNA test

UTSW study: RNA exosome key for B cell development

miRecule and Sanofi partner to develop muscular dystrophy therapy

New open-source software automates RNA analysis to speed up research and drug development

Laronde sets out to advance Endless RNA: ‘eRNA therapeutics have the potential to be an essential and widespread class of medicines’

Scientists develop RNA-targeting strategy to repair genetic cause of ALS and dementia

Ipsen, Skyhawk Ink Potential $1.8B Deal to Target RNA in Neuro Diseases

Stay Connected